Should you buy Tyra Biosciences (TYRA)?
Updated
Tyra Biosciences is a cash-burning clinical-stage biotechnology company focused on oral dabogratinib with 57% analyst upside and institutional accumulation, but a quality score of 1.2 out of 10, a put/call ratio of 88, and an implied volatility of 207% reflect extreme uncertainty around the binary clinical outcome.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
A put/call ratio of 88.0 and implied volatility of 207% are among the highest in the entire universe, indicating that the options market is pricing an extreme probability of a large binary move in either direction. Options | Implied volatility falls below 100% within 12 months following a clinical data release that reduces the binary uncertainty, regardless of outcome direction. | →Stable |
| CounterThe extreme put/call ratio may partially reflect hedging by biotech arbitrageurs rather than pure bearish conviction, meaning the ratio could overstate the actual probability of a severe downside move. | ||
The company's investment thesis rests almost entirely on the oral dabogratinib program, a single asset concentration that means clinical success or failure will determine the majority of the stock's long-term value. Bear case | Dabogratinib advances to at least one pivotal trial or achieves a clinical milestone within 12 months that narrows uncertainty around the regulatory pathway. | →Stable |
| CounterSingle-asset concentration in biotechnology eliminates diversification benefit, and a clinical setback could cause the stock to decline more than 50% below the current price of $28.55. | ||
Institutional investors are actively accumulating shares, reflected in a holder change score of 10 out of 10, suggesting that sophisticated capital believes the risk-reward is favorable at current prices ahead of upcoming data. Insider breakdown | Institutional ownership percentage increases by at least 5 percentage points over the next 12 months as additional funds initiate or expand positions. | →Stable |
| CounterInstitutional accumulation in small biotechnology names can reverse quickly on disappointing interim data, and the $1.7 billion market cap means even modest institutional selling could pressure the stock significantly. | ||
A put/call ratio of 88.0 and implied volatility of 207% are among the highest in the entire universe, indicating that the options market is pricing an extreme probability of a large binary move in either direction.
→Stable- Expectation
- Implied volatility falls below 100% within 12 months following a clinical data release that reduces the binary uncertainty, regardless of outcome direction.
CounterThe extreme put/call ratio may partially reflect hedging by biotech arbitrageurs rather than pure bearish conviction, meaning the ratio could overstate the actual probability of a severe downside move.
The company's investment thesis rests almost entirely on the oral dabogratinib program, a single asset concentration that means clinical success or failure will determine the majority of the stock's long-term value.
→Stable- Expectation
- Dabogratinib advances to at least one pivotal trial or achieves a clinical milestone within 12 months that narrows uncertainty around the regulatory pathway.
CounterSingle-asset concentration in biotechnology eliminates diversification benefit, and a clinical setback could cause the stock to decline more than 50% below the current price of $28.55.
Institutional investors are actively accumulating shares, reflected in a holder change score of 10 out of 10, suggesting that sophisticated capital believes the risk-reward is favorable at current prices ahead of upcoming data.
→Stable- Expectation
- Institutional ownership percentage increases by at least 5 percentage points over the next 12 months as additional funds initiate or expand positions.
CounterInstitutional accumulation in small biotechnology names can reverse quickly on disappointing interim data, and the $1.7 billion market cap means even modest institutional selling could pressure the stock significantly.
▸ Show 1 more pillar▾ Show fewer
Analysts set a consensus target of $44.89 against the current price of $28.55, implying 57% upside, supported by a sentiment score of 8.2 out of 10 and a news sentiment reading of +0.35 from 9 articles.
→Stable- Expectation
- Analyst consensus price target stays above $40 over the next 12 months as coverage firms maintain confidence in the clinical program.
CounterWith earnings misses of -8.6% and -8.5% in the two most recent quarters, the company is burning cash faster than expected, which could force a dilutive equity raise that reduces per-share value.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1The company's investment thesis rests almost entirely on the oral dabogratinib program, a single asset concentration that means clinical success or failure will determine the majority of the stock's long-term value.
Trip ifPrice drops below $20, more than 30% below the current $28.55, following a negative clinical update for the dabogratinib program.
- P2Institutional investors are actively accumulating shares, reflected in a holder change score of 10 out of 10, suggesting that sophisticated capital believes the risk-reward is favorable at current prices ahead of upcoming data.
Trip ifInstitutional holder change score falls below 5.0, suggesting net institutional selling has replaced the current accumulation trend.
- P3Analysts set a consensus target of $44.89 against the current price of $28.55, implying 57% upside, supported by a sentiment score of 8.2 out of 10 and a news sentiment reading of +0.35 from 9 articles.
Trip ifAnalyst consensus price target falls below $30, less than 5% above the current price of $28.55, indicating broad analyst capitulation on the upside case.
- P4A put/call ratio of 88.0 and implied volatility of 207% are among the highest in the entire universe, indicating that the options market is pricing an extreme probability of a large binary move in either direction.
Trip ifImplied volatility rises above 250%, more than 20% above the already-extreme 207% level, signaling that market makers are pricing even higher binary risk ahead of a data event.
How the engine reached this verdict
TrendMatrix's engine output for Tyra Biosciences, Inc. (TYRA) is SELL_IF_HOLDING with medium conviction, score 5.5/10 at $30.59. An L1 hard-floor gate blocked the positive-verdict path — Quality below minimum threshold; dimensional pillars cannot lift the engine output above the verdict floor while the L1 gate is active.
The engine's exit framework anchors to a tactical sell band near $30.59, with structural invalidation at $28.39. The asymmetric R:R against a reversal hypothesis is 6.87 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
On the bear side: Concentration risk — Pipeline: oral dabogratinib; Concentration risk — Supplier: third parties; Quality below floor (1.2 < 4.0). Active engine warnings: Quality below floor (1.2 < 4.0).
SELL output reflects multiple gate failures; recovery requires a confluence of those gates re-clearing, not a single dimension move.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates TYRA — 10-dimension breakdown →
Bear case
- ▸Concentration risk — Pipeline: oral dabogratinib
- ▸Concentration risk — Supplier: third parties
- ▸Quality below floor (1.2 < 4.0)